Enteric Coating Reduces Upper Gastrointestinal Adverse Reactions to Doxycycline

Area of Science:

• Pharmacology
• Gastroenterology
• Clinical Trials

Background:

• Doxycycline is a widely used antibiotic with known gastrointestinal side effects.
• Existing doxycycline formulations, including doxycycline monohydrate, can cause adverse reactions.
• New formulations aim to improve patient tolerability and adherence.

Purpose of the Study:

• To compare the gastrointestinal tolerability of a novel enteric-coated doxycycline hyclate pellet formulation.
• To evaluate adverse reactions against placebo and doxycycline monohydrate tablets.
• To assess the safety profile of the new doxycycline formulation in healthy volunteers.

Main Methods:

• Randomised, double-blind, 3-way crossover study design.
• 111 healthy volunteers received enteric-coated doxycycline hyclate, doxycycline monohydrate, or placebo for 3 consecutive days.
• Standardized administration protocols included fasting, water intake, and upright posture maintenance.

Main Results:

• Adverse reactions were reported by 30% (placebo), 43% (enteric-coated doxycycline hyclate), and 66% (doxycycline monohydrate).
• Doxycycline monohydrate caused significantly more adverse reactions, including abdominal pain, nausea, and vomiting.
• The enteric-coated formulation showed significantly better gastrointestinal tolerability than doxycycline monohydrate.

Conclusions:

• Enteric-coated doxycycline hyclate pellets in capsules offer superior gastrointestinal tolerability compared to doxycycline monohydrate.
• The new formulation may reduce the incidence of common doxycycline-related GI adverse events.
• This formulation represents a promising advancement in doxycycline therapy for improved patient compliance.